Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.

Published on Feb 1, 2020in The Prostate3.279
· DOI :10.1002/PROS.23935
Erik Bovinder Ylitalo5
Estimated H-index: 5
(Umeå University),
Elin Thysell14
Estimated H-index: 14
(Umeå University)
+ 6 AuthorsPernilla Wikström37
Estimated H-index: 37
(Umeå University)
Sources
Abstract
BACKGROUND: Taxane treatment may be a suitable therapeutic option for patients with castration-resistant prostate cancer and high expression of constitutively active androgen receptor variants (AR-Vs). The aim of the study was to compare the effects of cabazitaxel and androgen deprivation treatments in a prostate tumor xenograft model expressing high levels of constitutively active AR-V7. Furthermore, mechanisms behind acquired cabazitaxel resistance were explored. METHODS: Mice were subcutaneously inoculated with 22Rv1 cells and treated with surgical castration (n = 7), abiraterone (n = 9), cabazitaxel (n = 6), castration plus abiraterone (n = 8), castration plus cabazitaxel (n = 11), or vehicle and/or sham operation (n = 23). Tumor growth was followed for about 2 months or to a volume of approximately 1000 mm(3) . Two cabazitaxel resistant cell lines; 22Rv1-CabR1 and 22Rv1-CabR2, were established from xenografts relapsing during cabazitaxel treatment. Differential gene expression between the cabazitaxel resistant and control 22Rv1 cells was examined by whole-genome expression array analysis followed by immunoblotting, immunohistochemistry, and functional pathway analysis. RESULTS: Abiraterone treatment alone or in combination with surgical castration had no major effect on 22Rv1 tumor growth, while cabazitaxel significantly delayed and in some cases totally abolished 22Rv1 tumor growth on its own and in combination with surgical castration. The cabazitaxel resistant cell lines; 22Rv1-CabR1 and 22Rv1-CabR2, both showed upregulation of the ATP-binding cassette sub-family B member 1 (ABCB1) efflux pump. Treatment with ABCB1 inhibitor elacridar completely restored susceptibility to cabazitaxel, while treatment with AR-antagonists bicalutamide and enzalutamide partly restored susceptibility to cabazitaxel in both cell lines. The cholesterol biosynthesis pathway was induced in the 22Rv1-CabR2 cell line, which was confirmed by reduced sensitivity to simvastatin treatment. CONCLUSIONS: Cabazitaxel efficiently inhibits prostate cancer growth despite the high expression of constitutively active AR-V7. Acquired cabazitaxel resistance involving overexpression of efflux transporter ABCB1 can be reverted by bicalutamide or enzalutamide treatment, indicating the great clinical potential for combined treatment with cabazitaxel and anti-androgens.
📖 Papers frequently viewed together
2020
1 Author (Diane Begemann)
References34
Newest
#1Alan P. Lombard (UC Davis: University of California, Davis)H-Index: 9
#2Liangren Liu (Sichuan University)H-Index: 3
Last. Allen C. Gao (UC Davis: University of California, Davis)H-Index: 58
view all 10 authors...
Current treatments for castration resistant prostate cancer (CRPC) largely fall into two major classes; AR-targeted therapies such as the next-generation anti-androgen therapies (NGATs), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between the...
16 CitationsSource
#1George E. Duran (Stanford University)H-Index: 26
#2Volker DerdauH-Index: 20
Last. Branimir I. Sikic (Stanford University)H-Index: 75
view all 10 authors...
Purpose The primary aim of this study was to determine cabazitaxel’s affinity for the ABCB1/P-glycoprotein (P-gp) transporter compared to first-generation taxanes.
12 CitationsSource
#1Kazuaki Machioka (Kanazawa University)H-Index: 7
#2Kouji Izumi (Kanazawa University)H-Index: 17
Last. Atsushi Mizokami (Kanazawa University)H-Index: 42
view all 11 authors...
// Kazuaki Machioka 1 , Kouji Izumi 1 , Yoshifumi Kadono 1 , Hiroaki Iwamoto 1 , Renato Naito 1 , Tomoyuki Makino 1 , Suguru Kadomoto 1 , Ariunbold Natsagdorj 1 , Evan T. Keller 2 , Jian Zhang 3 and Atsushi Mizokami 1 1 Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, 920-8640, Japan 2 Department of Urology, School of Medicine and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA 3 Center for Transla...
17 CitationsSource
#1Ping Tan (Sichuan University)H-Index: 9
#2Chen Zhang (Sichuan University)H-Index: 13
Last. Qiang Wei (Sichuan University)H-Index: 28
view all 7 authors...
The aim of this study is to investigate the effect of statins type or even when grouping statins by hydrophilic or hydrophobic nature on prostate cancer risk. A literature search was performed without language restrictions using the databases of PubMed (1984.1-2015.3), MEDLINE (1984.1-2015.3), and EMBASE (1990.1-2015.3). Two independent reviewers appraised eligible studies and extracted data. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CI). Statistic hete...
24 CitationsSource
#1Alan P. Lombard (UC Davis: University of California, Davis)H-Index: 9
#2Chengfei Liu (UC Davis: University of California, Davis)H-Index: 21
Last. Allen C. Gao (UC Davis: University of California, Davis)H-Index: 58
view all 8 authors...
in research have added several new therapies for castration-resistant prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC remains an incurable disease due to the development of therapeutic resistance and the existence of cross-resistance between available therapies. Understanding the interplay between different treatments will lead to improved sequencing and the creation of combinations which overcome resistance and prolong survival. Whether there exists cross...
27 CitationsSource
#1Erik Bovinder Ylitalo (Umeå University)H-Index: 5
#2Elin Thysell (Umeå University)H-Index: 14
Last. Pernilla Wikström (Umeå University)H-Index: 37
view all 10 authors...
Background: Novel therapies for men with castration-resistant prostate cancer (CRPC) are needed, particularly for cancers not driven by androgen receptor (AR) activation. Objectives: To identify mo ...
59 CitationsSource
#1Emmanuel S. Antonarakis (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 11
#1Emmanuel S. Antonarakis (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 63
Last. Jun LuoH-Index: 76
view all 15 authors...
PurposeWe reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abiraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC). Here, we expanded our cohort size to better characterize the prognostic significance of AR-V7 in this setting.MethodsWe prospectively enrolled 202 patients with CRPC starting abiraterone or enzalutamide and investigated the progn...
259 CitationsSource
#1Fangfang Qu (Harvard University)H-Index: 9
#2Wanling Xie (Harvard University)H-Index: 51
Last. Philip W. Kantoff (Harvard University)H-Index: 134
view all 11 authors...
Purpose: We evaluated the association of PSA and androgen receptor splice variant-7 (AR-V7) transcript levels in patients9 blood with time to treatment failure (TTF) and overall survival (OS) with abiraterone acetate and/or enzalutamide treatment in castration-resistant prostate cancer (CRPC) patients. Experimental Design: RNA levels of AR-V7 and PSA in peripheral blood collected before treatment were quantified using droplet digital-PCR in retrospective cohorts treated with abiraterone acetate ...
77 CitationsSource
#1Howard I. Scher (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 145
#1Howard I. Scher (Cornell University)H-Index: 62
Last. Ryan DittamoreH-Index: 19
view all 17 authors...
Importance A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. Objective To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes. Design, Setting, and Participants For this cross-sectional ...
397 CitationsSource
#1Diego Iglesias-Gato (UCPH: University of Copenhagen)H-Index: 15
#2Pernilla Wikström (Umeå University)H-Index: 37
Last. Amilcar Flores-Morales (UCPH: University of Copenhagen)H-Index: 35
view all 18 authors...
Background: Clinical management of the prostate needs improved prognostic tests and treatment strategies. Because proteins are the ultimate effectors of most cellular reactions, are targets for dru ...
88 CitationsSource
Cited By7
Newest
#1Qinchen Li (ZJU: Zhejiang University)H-Index: 2
#2Zhize Wang (ZJU: Zhejiang University)H-Index: 2
view all 7 authors...
Source
#1Roberto H. Barbier (NIH: National Institutes of Health)H-Index: 1
#2Edel M. McCrea (NIH: National Institutes of Health)H-Index: 4
Last. William D. Figg (NIH: National Institutes of Health)H-Index: 121
view all 8 authors...
Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority. The organic anion polypeptide 1B3 (OATP1B3, encoded by SLCO1B3) transporter has been shown to transport androgens into prostate cancer cells. In this study we observed and investigated the mechanism of induction of SLCO1B3 by abiraterone. Prostate cancer cells (22Rv1, LNCaP, and VCAP) were treated with anti-androgens and assessed ...
1 CitationsSource
#1Seiji Hishida (Gidai: Gifu University)
#2Kyojiro KawakamiH-Index: 9
Last. Kosuke Mizutani (Gidai: Gifu University)H-Index: 13
view all 12 authors...
Background Cabazitaxel (CBZ) is now widely used for prostate cancer (PC) patients resistant to docetaxel (DOC), however, most patients eventually acquire resistance. It will, therefore, be of great benefit to discover novel therapeutic target for the resistance. We aimed to identify candidate therapeutic targets for CBZ-resistance by proteomic analysis of extracellular vesicles (EVs) isolated from serum of DOC-resistant PC patients who later developed CBZ-resistance as well as those harvested fr...
Source
#1Shiqi LiH-Index: 1
#2Fuhui Zhang (Sichuan University)H-Index: 1
Last. Xuemei PuH-Index: 14
view all 7 authors...
Prostate cancer (PRAD) is a major cause of cancer-related deaths. Current monotherapies show limited efficacy due to often rapidly emerging resistance. Combination therapies could provide an alternative solution to address this problem with enhanced therapeutic effect, reduced cytotoxicity, and delayed the appearance of drug resistance. However, it is prohibitively cost and labor-intensive for the experimental approaches to pick out synergistic combinations from the millions of possibilities. Th...
Source
Introduction: The armamentarium of treatment options in metastatic and non-metastatic CRPC is rapidly evolving. However, the question of how individual treatment decisions should be balanced by ava...
Source
#1Vadim S. PokrovskyH-Index: 10
view all 11 authors...
Source
#1Alan P. Lombard (UC Davis: University of California, Davis)H-Index: 9
#2Liangren Liu (Sichuan University)H-Index: 3
Last. Allen C. Gao (UC Davis: University of California, Davis)H-Index: 58
view all 10 authors...
Current treatments for castration resistant prostate cancer (CRPC) largely fall into two major classes; AR-targeted therapies such as the next-generation anti-androgen therapies (NGATs), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between the...
16 CitationsSource